Meyers D, Rittberg R, Dawe D, Banerji S
Curr Oncol. 2024; 31(9):5498-5515.
PMID: 39330035
PMC: 11431477.
DOI: 10.3390/curroncol31090407.
Nagano M, Cong Y, Nakao K, Kawashima M, Konoeda C, Sato M
Surg Today. 2024; .
PMID: 39320491
DOI: 10.1007/s00595-024-02917-8.
Lasheen N, Allam S, Elgarawany A, Aswa D, Mansour R, Farouk Z
J Physiol Sci. 2024; 74(1):46.
PMID: 39313800
PMC: 11421184.
DOI: 10.1186/s12576-024-00933-4.
Borgers J, van Wesemael T, Gelderman K, Rispens T, Verdegaal E, Moes D
J Immunother Cancer. 2024; 12(6).
PMID: 38945553
PMC: 11216046.
DOI: 10.1136/jitc-2024-009215.
Shah N, Della Pia A, Wu T, Williams A, Weber M, Sinclaire B
Cancers (Basel). 2024; 16(12).
PMID: 38927928
PMC: 11202168.
DOI: 10.3390/cancers16122223.
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
von Itzstein M, Yang Y, Wang Y, Hsiehchen D, Sheffield T, Fattah F
Front Immunol. 2024; 15:1351739.
PMID: 38690281
PMC: 11058939.
DOI: 10.3389/fimmu.2024.1351739.
Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis.
Liu X, Li S, Ke L, Cui H
BMC Cancer. 2024; 24(1):490.
PMID: 38632528
PMC: 11025164.
DOI: 10.1186/s12885-024-12256-z.
Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments.
Kokkotou E, Anagnostakis M, Evangelou G, Syrigos N, Gkiozos I
Cancers (Basel). 2024; 16(7).
PMID: 38611092
PMC: 11010882.
DOI: 10.3390/cancers16071414.
Immune Checkpoint Inhibitor-Associated Systemic Sclerosis in the Treatment of a Small Cell Lung Cancer Patient with Durvalumab: A Case Report.
Li D, Xiong X
Clin Cosmet Investig Dermatol. 2024; 17:663-669.
PMID: 38524396
PMC: 10959325.
DOI: 10.2147/CCID.S451386.
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer.
Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A
Int J Clin Oncol. 2023; 29(2):124-133.
PMID: 38160406
DOI: 10.1007/s10147-023-02445-4.
Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events.
Altan M, Li Q, Wang Q, Vokes N, Sheshadri A, Gao J
Front Immunol. 2023; 14:1322818.
PMID: 38152395
PMC: 10751952.
DOI: 10.3389/fimmu.2023.1322818.
IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer.
Liao H, Chang X, Gao L, Ye C, Qiao Y, Xie L
J Transl Med. 2023; 21(1):828.
PMID: 37978543
PMC: 10656985.
DOI: 10.1186/s12967-023-04365-3.
An immunomodulating peptide with potential to suppress tumour growth and autoimmunity.
Agrez M, Chandler C, Thurecht K, Fletcher N, Liu F, Subramaniam G
Sci Rep. 2023; 13(1):19741.
PMID: 37957274
PMC: 10643673.
DOI: 10.1038/s41598-023-47229-y.
Improved lung cancer clinical outcomes in patients with autoimmune rheumatic diseases.
Ghanem P, Murray J, Marrone K, Scott S, Feliciano J, Lam V
RMD Open. 2023; 9(4).
PMID: 37914179
PMC: 10619011.
DOI: 10.1136/rmdopen-2023-003471.
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study.
McCarter K, Wolfgang T, Arabelovic S, Wang X, Yoshida K, Banasiak E
Lancet Rheumatol. 2023; 5(5):e274-e283.
PMID: 37841635
PMC: 10571093.
DOI: 10.1016/s2665-9913(23)00064-4.
Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events.
Gente K, Diekmann L, Daniello L, Will J, Feisst M, Olsavszky V
J Immunother Cancer. 2023; 11(9).
PMID: 37730272
PMC: 10510926.
DOI: 10.1136/jitc-2023-007557.
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors.
Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J
Cancers (Basel). 2023; 15(15).
PMID: 37568819
PMC: 10416973.
DOI: 10.3390/cancers15154004.
Toxicity, disease management and outcome of treatment with immune checkpoint inhibitors by sex in patients with cancer and preexisting autoimmune disease.
Liu M, Christ L, Richters A, Ozdemir B
Oncol Lett. 2023; 26(3):377.
PMID: 37559593
PMC: 10407854.
DOI: 10.3892/ol.2023.13963.
A 71-year-old male with a life-threatening recurrence of hemolytic anemia, thrombocytopenia, and acute kidney injury after pembrolizumab therapy: a case report.
Zhang X, Gao B, Guo C, Su T
BMC Geriatr. 2023; 23(1):478.
PMID: 37553570
PMC: 10410872.
DOI: 10.1186/s12877-023-04181-w.
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases.
Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis V
Front Immunol. 2023; 14:1197364.
PMID: 37342323
PMC: 10277501.
DOI: 10.3389/fimmu.2023.1197364.
